{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:32:33Z","timestamp":1790987553997,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.lungcan.2013.01.015","type":"journal-article","created":{"date-parts":[[2013,2,14]],"date-time":"2013-02-14T14:33:00Z","timestamp":1360852380000},"page":"197-202","source":"Crossref","is-referenced-by-count":20,"title":["Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study"],"prefix":"10.1016","volume":"80","clinical-trial-number":[{"clinical-trial-number":"nct00961415","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"St\u00e9fanie","family":"Habib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Delourme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Dhalluin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Petyt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Tacelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Lafitte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis B.","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2013.01.015_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0010","first-page":"61","article-title":"Phase III trial (E5592) comparing cisplatin plus etoposide with cisplatin plus paclitaxel at two dose levels for treatment of advanced non-small-cell lung cancer. Eastern Cooperative Oncology Group","author":"Johnson","year":"1995","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0015","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1158\/1535-7163.1301.3.10","article-title":"Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway","volume":"3","author":"Pasquier","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0020","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0025","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ccr.2008.08.001","article-title":"Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents","volume":"14","author":"Shaked","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0035","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0040","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","article-title":"Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer","volume":"22","author":"Johnson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0050","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cllc.2011.06.008","article-title":"Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer","volume":"13","author":"Asahina","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0060","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(02)00308-2","article-title":"A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer","volume":"39","author":"Massarelli","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcma.2011.03.005","article-title":"Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status","volume":"74","author":"Chen","year":"2011","journal-title":"J Chin Med Assoc"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.lungcan.2009.12.002","article-title":"The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer","volume":"69","author":"Chang","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0075","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0080","first-page":"1226","article-title":"Bevacizumab in advanced lung cancer: in search of the right drug for the right patient","volume":"24","author":"Burns","year":"2010","journal-title":"Oncology (Williston Park, NY)"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0085","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2 \u2013 negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0090","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2 \u2013 negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0095","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1200\/JCO.2009.23.6406","article-title":"Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426","volume":"28","author":"Adjei","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0100","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","article-title":"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial","volume":"377","author":"Herbst","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0105","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","article-title":"Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)","volume":"26","author":"Grothey","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cllc.2011.05.002","volume":"12","author":"Gridelli","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0115","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"27","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0120","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/JTO.0b013e3182208fc2","article-title":"Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer","volume":"6","author":"Lee","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0125","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1038\/leu.2011.168","article-title":"Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas","volume":"25","author":"Dejean","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0130","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1470-2045(09)70112-3","article-title":"Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis","volume":"10","author":"Hapani","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11523-006-0012-7","article-title":"Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs. triweekly regimens","volume":"1","author":"Saito","year":"2006","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0140","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/JTO.0b013e3181f77b6e","article-title":"Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group","volume":"5","author":"Jalal","year":"2010","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.lungcan.2013.01.015_bib0145","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.lungcan.2012.02.002","article-title":"Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group","volume":"77","author":"Mountzios","year":"2012","journal-title":"Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500213000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T14:47:30Z","timestamp":1688050050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500213000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0169500213000251"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2013.01.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}